• Explore /
  • Poster
  • / CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.

CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.

Abstract Video & Slides Poster

Authors

null

Simon J. Crabb

Southampton Clinical Trials Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

Simon J. Crabb , Ding-Wei Ye , Hirotsugu Uemura , Thomas Morris , Christopher Gresty , Jill Logan , Claire Rooney , Andrew Foxley , Michael Anthony Carducci

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05348577

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr TPS287)

DOI

10.1200/JCO.2023.41.6_suppl.TPS287

Abstract #

TPS287

Poster Bd #

Q9

Abstract Disclosures

Similar Posters

First Author: Johann S. De Bono

First Author: Sumit Kumar Subudhi

First Author: Dana E. Rathkopf

First Author: Christopher Sweeney